Table 2. Characteristics of patients followed from 10 years after start of ART who died, were lost to follow up (LTFU) or remained in the study until end of follow up.
| Number (%) of patients | |||
|---|---|---|---|
| Died (N = 656) | LTFU (N = 2,708) | Remained in the study (N = 9,647) | |
| IDU | 121 (18%) | 474 (18%) | 1,041 (11%) |
| Female | 81 (12%) | 669 (25%) | 1,951 (20%) |
| No AIDS | 302 (46%) | 1,867 (69%) | 6,492 (67%) |
| AIDS before ART start | 175 (27%) | 537 (20%) | 2,002 (21%) |
| AIDS between ART start and 10 years afterwards | 179 (27%) | 304 (11%) | 1,153 (12%) |
| Age (years) | |||
| Median (IQR) | 52 (45, 60) | 45 (40, 51) | 46 (41, 53) |
| 16–39 | 53 (8%) | 606 (22%) | 1,671 (17%) |
| 40–49 | 225 (34%) | 1,287 (48%) | 4,517 (47%) |
| 50–59 | 200 (30%) | 570 (21%) | 2,359 (24%) |
| ≥60 | 178 (27%) | 245 (9%) | 1,100 (11%) |
| CD4 count (cells/μL) | |||
| Median (IQR) | 383 (185, 554) | 535 (350, 740) | 566 (390, 774) |
| 0–99 | 98 (15%) | 97 (4%) | 205 (2%) |
| 100–199 | 81 (12%) | 176 (7%) | 371 (4%) |
| 200–349 | 131 (20%) | 398 (15%) | 1,321 (14%) |
| 350–499 | 128 (20%) | 532 (20%) | 1,984 (21%) |
| 500–749 | 126 (19%) | 856 (32%) | 3,111 (32%) |
| ≥750 | 92 (14%) | 649 (24%) | 2655 (28%) |
| Viral load (HIV-1 RNA copies/mL) | |||
| % with RNA≤50 | 56% | 73% | 77% |
| 0–50 | 370 (56%) | 1,977 (73%) | 7,467 (77%) |
| 51–1000 | 119 (18%) | 365 (13%) | 1,206 (13%) |
| >1000 | 167 (25%) | 366 (14%) | 974 (10%) |
IDU: injection drug use; IQR: inter-quartile range